FDA Approves Roivant's Lisraya (Brepocitinib) as First Targeted Therapy for Dermatomyositis

FDA Approves Roivant's Lisraya (Brepocitinib) as First Targeted Therapy for Dermatomyositis

On August 27, 2026, the U.S. Food and Drug Administration (FDA) approved Roivant Sciences and Priovant Therapeutics' Lisraya (brepocitinib) 30 mg as a once-daily oral treatment for adults with dermatomyositis (DM). This represents a major therapeutic milestone as the first-ever targeted and first-ever oral therapy approved for this rare, debilitating systemic autoimmune disease¹, which is characterized by painful skin lesions and progressive muscle weakness.

The approval is supported by robust efficacy data from the landmark Phase 3 VALOR trial (NCT05437263), the largest clinical trial ever conducted in dermatomyositis, which randomized 241 adults to receive once-daily brepocitinib (30 mg or 15 mg) or placebo over 52 weeks.

Key Trial Findings & Clinical Performance

• Primary Endpoint Met: In the VALOR trial, patients treated with Lisraya demonstrated rapid and sustained improvements on the myositis Total Improvement Score (TIS), a composite measure of disease activity across multiple domains. Efficacy was observed as early as Week 4 and sustained through the 52-week study period.
• Broad Manifestation Control: Lisraya showed significant improvements across independent measures of muscle strength, skin lesions, and patient-reported outcomes. Treated patients reported more than a four-fold improvement in overall disease activity compared to the placebo group.
• Steroid-Sparing Benefits: The trial demonstrated substantial steroid-sparing benefits, allowing patients to reduce background corticosteroid use while maintaining disease control.
• Tolerability and Safety: The most common adverse reactions reported in the VALOR trial included upper respiratory tract infections, headache, fatigue, urinary tract infections, nausea, and bronchitis. As a TYK2/JAK1 inhibitor, the drug's prescribing information includes a boxed warning for serious infections, major adverse cardiovascular events (MACE), thrombosis, and malignancies.

Strategic and Market Context

Lisraya's approval follows the FDA's previous decisions to grant the program Priority Review and Orphan Drug Designation. Roivant and Priovant made the therapy available in the U.S. immediately upon approval through a limited specialty pharmacy distribution network. Analysts project blockbuster potential for brepocitinib, with sales estimates ranging from $5 billion to $10 billion across multiple targeted autoimmune and inflammatory indications.